Safety of Regadenoson in Patients with End-Stage Renal Disease
To access this article, please choose from the options below
Dr. Iskandrian is a consultant to Gilead Sciences, Inc., Foster City, California, and to Astellas Pharma Global Development, Inc., Deerfield, Illinois.
PII: S0002-9149(09)02228-0
doi:10.1016/j.amjcard.2009.08.663
© 2010 Elsevier Inc. All rights reserved.
